Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 478

1.

Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.

Ling Z, Zhang M, Hu Y, Yin Z, Xing Y, Fang A, Ye J, Chen X, Liu D, Wang Y, Sun W, Dong Y, Sun X.

Chin Med J (Engl). 2014;127(5):905-10.

PMID:
24571886
3.

Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study.

Feuerhake C, Buchholz P, Kimmich F.

Curr Med Res Opin. 2009 Apr;25(4):1037-43. doi: 10.1185/03007990902816947 .

PMID:
19290780
5.

Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.

Rossetti L, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M, Boehm A, Viswanathan A, Vorwerk C, Goldblum D.

Ophthalmology. 2007 Dec;114(12):2244-51. Epub 2007 Apr 25.

PMID:
17459480
7.

Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension.

Katsanos A, Dastiridou AI, Fanariotis M, Kotoula M, Tsironi EE.

J Ocul Pharmacol Ther. 2011 Feb;27(1):67-71. doi: 10.1089/jop.2010.0090. Epub 2011 Jan 7.

PMID:
21214361
8.

A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.

Topouzis F, Melamed S, Danesh-Meyer H, Wells AP, Kozobolis V, Wieland H, Andrew R, Wells D.

Eur J Ophthalmol. 2007 Mar-Apr;17(2):183-90.

PMID:
17415690
9.

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.

Wang K, Xu L, Yuan Z, Yao K, Zhao J, Xu L, Fang A, Zhang M, Wu L, Ji J, Hou J, Liu Q, Sun X.

BMC Ophthalmol. 2014 Feb 25;14:21. doi: 10.1186/1471-2415-14-21.

12.

Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.

Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I; Ganfort Investigators Group II.

J Glaucoma. 2008 Apr-May;17(3):211-6. doi: 10.1097/IJG.0b013e3181507313. Erratum in: J Glaucoma. 2010 Aug;19(6):423.

PMID:
18414107
13.

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.

Goldberg I, Gil Pina R, Lanzagorta-Aresti A, Schiffman RM, Liu C, Bejanian M.

Br J Ophthalmol. 2014 Jul;98(7):926-31. doi: 10.1136/bjophthalmol-2013-304064. Epub 2014 Mar 25.

14.

Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%.

Scherzer ML, Liehneova I, Negrete FJ, Schnober D.

Adv Ther. 2011 Aug;28(8):661-70. doi: 10.1007/s12325-011-0043-z. Epub 2011 Jul 15.

PMID:
21773673
16.

Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Easthope SE, Perry CM.

Drugs Aging. 2002;19(3):231-48. Review.

PMID:
12027782
17.

The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.

Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA, Bergamini MV.

Am J Ophthalmol. 2005 Jul;140(1):1-7.

PMID:
15990081
18.

Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.

Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL; Bimatoprost Study Group.

Br J Ophthalmol. 2008 Oct;92(10):1387-92. doi: 10.1136/bjo.2007.128454. Epub 2008 Jul 11.

PMID:
18621791
19.
20.

A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.

Facio AC, Reis AS, Vidal KS, de Moraes CG, Suzuki R, Hatanaka M, Susanna R.

J Ocul Pharmacol Ther. 2009 Oct;25(5):447-51. doi: 10.1089/jop.2009.0018.

PMID:
19860553

Supplemental Content

Support Center